Find clinical trials for Non-Hodgkin Lymphoma in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia

Non-Hodgkin Lymphoma trials near Boston, MA, USA:

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

This is a Phase 1/2 study of imvotamab in adult subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This stu...

Active, not recruiting
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Drug: imvotamab

Phase 1, Phase 2

IGM Biosciences

Boston, Massachusetts, United States and 26 other locations

administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) admin...

Lymphoma, Non-Hodgkin's
Multiple Myeloma
Drug: Dexamethasone Oral
Drug: CFT7455

Phase 1, Phase 2

C4 Therapeutics

Boston, Massachusetts, United States and 12 other locations

in participants with relapsed or refractory (R/R) CD30-expressing lymphomas.GEN3017 will be administered via subcutaneous injections.All par...

Classical Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biological: GEN3017

Phase 1, Phase 2


Boston, Massachusetts, United States and 4 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2


Boston, Massachusetts, United States and 37 other locations

to define the recommended dose for phase 2 for the combination.The study is focused on patients with relapsed or refractory aggressive B-cell non...

B-cell Non-Hodgkins Lymphoma (B-NHL)
Drug: REGN5837
Drug: Odronextamab

Phase 1

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Boston, Massachusetts, United States and 13 other locations

patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas wh...

Active, not recruiting
Non-Hodgkin's Lymphoma
Small Lymphocytic Lymphoma
Drug: CG-806

Phase 1

Aptose Biosciences

Worcester, Massachusetts, United States and 29 other locations

intravenously in subjects with relapsed or refractory B-Cell Non-Hodgkin Lymphoma (B-NHL). The purpose of this study is to...

B-cell Non-Hodgkin Lymphoma (B-NHL)
Biological: UCART20x22
Biological: CLLS52

Phase 1, Phase 2


Boston, Massachusetts, United States and 8 other locations

in participants with relapsed or refractory (R/R) solid tumors or non-Hodgkin lymphoma (NHL).Part 2: Cohort Expansion. The...

Non-Hodgkin Lymphoma
Relapsed Solid Tumors
Drug: KB-0742

Phase 1, Phase 2

Kronos Bio

Boston, Massachusetts, United States and 25 other locations

017 works in treating patients with non-Hodgkin's lymphoma whose disease has come back or has not responded to treatment....

Active, not recruiting
Follicular Lymphoma
Mantle-cell Lymphoma
Biological: JCAR017 (lisocabtagene maraleucel) single-dose schedule
Biological: JCAR017 (lisocabtagene maraleucel) 2-dose schedule

Phase 1

Juno Therapeutics

Boston, Massachusetts, United States and 13 other locations

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non...

Active, not recruiting
NHL, Relapsed, Adult
Drug: CLN-978

Phase 1

Cullinan Therapeutics Inc.

Boston, Massachusetts, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems